Monitor for Phase 1 safety and PK/PD data expected by mid-2027. No near-term catalyst; stock movement will depend on broader pipeline updates or financing news.
Price Chart
Executive Summary
Hemab Therapeutics dosed the first healthy volunteer in a Phase 1 trial of HMB-003, a novel peptide-based antifibrinolytic for heavy menstrual bleeding. The trial is early-stage and results are not expected until mid-2027, making this a routine clinical milestone with no immediate stock-moving catalyst.
Key Facts
- First healthy volunteer dosed in Phase 1 trial of HMB-003 for heavy menstrual bleeding.
- HMB-003 is a subcutaneously administered peptide-based plasmin inhibitor with once-per-cycle dosing potential.
- Phase 1 study (NCT07798505) is a randomized, placebo-controlled, single-ascending-dose escalation trial in healthy volunteers.
- Results expected no later than mid-2027 to inform dose selection and development plans.
- Heavy menstrual bleeding affects ~23 million women in the U.S. annually; no approved non-hormonal long-acting treatment exists.
Financial Impact
No financial data disclosed; early clinical-stage with no revenue or guidance.
Risk Factors
- Phase 1 trial may fail to demonstrate safety or tolerability.
- HMB-003 is early-stage; clinical development timeline is long and uncertain.
- Hemab is a clinical-stage biotech with no approved products or revenue; cash burn risk.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3363905 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | 3 | $33.12 $36.02 | ▲ +8.76% | ▲ +8.79% | $38.40 (+15.94%) |
Sep 17, 2026 5w ago | Press Release | $41.22 $32.52 | ▼ −21.11% | ▼ −22.56% | $38.40 (−6.84%) |
Aug 11, 2026 11w ago | 8-K | $49.87 $44.50 | ▼ −10.77% | ▼ −9.71% | $38.40 (−23.00%) |
Jun 17, 2026 18w ago | Insider Buy | $29.24 $44.53 | ▲ +52.29% | ▲ +51.76% | $38.40 (+31.33%) |
May 21, 2026 22w ago | Press Release | $26.30 $31.83 | ▲ +21.03% | ▲ +20.69% | $38.40 (+46.01%) |
May 4, 2026 25w ago | 8-K | $25.00 $27.47 | ▲ +9.88% | ▲ +4.93% | $38.40 (+53.60%) |
Apr 30, 2026 25w ago | Press Release | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $38.40 (+12.94%) |
Apr 30, 2026 25w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $38.40 (+12.94%) |
Apr 30, 2026 25w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $38.40 (+12.94%) |
Apr 30, 2026 25w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $38.40 (+12.94%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers